Product Description
Ambroxol is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus. It is the active ingredient of Mucosolvan, Lasolvan or Mucoangin. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Ambroxol)
Mechanisms of Action: lipid peroxidation Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Inhalant
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Israel, Norway, Unknown Location
Active Clinical Trial Count: 16
Highest Development Phases
Phase 3: Asthma|Bronchitis, Chronic|Other|Respiratory Tract Infections|Rhinitis|Sinusitis
Phase 2: Amyotrophic Lateral Sclerosis|Dementia|Lewy Body Dementia|Lewy Body Disease|Parkinson's Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AGPI | P2 |
Recruiting |
Parkinson's Disease |
2025-02-27 |
|
| ANeED | P2 |
Recruiting |
Dementia|Lewy Body Dementia|Lewy Body Disease |
2024-12-01 |
|
| AMBALS | P2 |
Recruiting |
Amyotrophic Lateral Sclerosis |
2024-06-01 |
|
| High-dose Ambroxol as a disease-modifying treatment for Parkinson' disease | P2 |
Active, not recruiting |
Parkinson's Disease |
2024-03-08 |